Hypertension and atrial fibrillation

Diagnostic approach, prevention and treatment. Position paper of the Working Group 'Hypertension Arrhythmias and Thrombosis' of the European Society of Hypertension

Athanasios J. Manolis, Enrico Agabiti Rosei, Antonio Coca, Renata Cifkova, Serap E. Erdine, Sverre Kjeldsen, Gregory Y H Lip, Krzysztof Narkiewicz, Gianfranco Parati, Josep Redon, Roland Schmieder, Costas Tsioufis, Giuseppe Mancia

Research output: Contribution to journalArticle

119 Citations (Scopus)

Abstract

Hypertension is the most common cardiovascular disorder and atrial fibrillation is the most common clinically significant arrhythmia. Both these conditions frequently coexist and their prevalence increases rapidly with aging. There are different risk factors and clinical conditions predisposing to the development of atrial fibrillation, but due its high prevalence, hypertension is still the main risk factor for the development of atrial fibrillation. Several pathophysiologic mechanisms (such as structural changes, neurohormonal activation, fibrosis, atherosclerosis, etc.) have been advocated to explain the onset of atrial fibrillation. The presence of atrial fibrillation per se increases the risk of stroke but its coexistence with high blood pressure leads to an abrupt increase of cardiovascular complications. Different risk models are available for the risk stratification and the prevention of thromboembolism in patients with atrial fibrillation. In all of them hypertension is present and is an important risk factor. Antihypertensive treatment may contribute to reduce this risk, and it seems some classes are superior to others in the prevention of new-onset atrial fibrillation and prevention of stroke. Antithrombotic treatment with warfarin is effective in the prevention of thromboembolic events, although quite recently, new classes of anticoagulants that do not require international normalized ratio monitoring have been introduced with promising results.

Original languageEnglish
Pages (from-to)239-252
Number of pages14
JournalJournal of Hypertension
Volume30
Issue number2
DOIs
Publication statusPublished - Feb 2012

Fingerprint

Atrial Fibrillation
Cardiac Arrhythmias
Thrombosis
Hypertension
Therapeutics
Stroke
International Normalized Ratio
Thromboembolism
Warfarin
Anticoagulants
Antihypertensive Agents
Atherosclerosis
Fibrosis

Keywords

  • anticoagulants
  • antihypertensive treatment
  • atrial fibrillation
  • hypertension

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Hypertension and atrial fibrillation : Diagnostic approach, prevention and treatment. Position paper of the Working Group 'Hypertension Arrhythmias and Thrombosis' of the European Society of Hypertension. / Manolis, Athanasios J.; Rosei, Enrico Agabiti; Coca, Antonio; Cifkova, Renata; Erdine, Serap E.; Kjeldsen, Sverre; Lip, Gregory Y H; Narkiewicz, Krzysztof; Parati, Gianfranco; Redon, Josep; Schmieder, Roland; Tsioufis, Costas; Mancia, Giuseppe.

In: Journal of Hypertension, Vol. 30, No. 2, 02.2012, p. 239-252.

Research output: Contribution to journalArticle

Manolis, Athanasios J. ; Rosei, Enrico Agabiti ; Coca, Antonio ; Cifkova, Renata ; Erdine, Serap E. ; Kjeldsen, Sverre ; Lip, Gregory Y H ; Narkiewicz, Krzysztof ; Parati, Gianfranco ; Redon, Josep ; Schmieder, Roland ; Tsioufis, Costas ; Mancia, Giuseppe. / Hypertension and atrial fibrillation : Diagnostic approach, prevention and treatment. Position paper of the Working Group 'Hypertension Arrhythmias and Thrombosis' of the European Society of Hypertension. In: Journal of Hypertension. 2012 ; Vol. 30, No. 2. pp. 239-252.
@article{1b329f9eabdd4017aad1675e63f0afab,
title = "Hypertension and atrial fibrillation: Diagnostic approach, prevention and treatment. Position paper of the Working Group 'Hypertension Arrhythmias and Thrombosis' of the European Society of Hypertension",
abstract = "Hypertension is the most common cardiovascular disorder and atrial fibrillation is the most common clinically significant arrhythmia. Both these conditions frequently coexist and their prevalence increases rapidly with aging. There are different risk factors and clinical conditions predisposing to the development of atrial fibrillation, but due its high prevalence, hypertension is still the main risk factor for the development of atrial fibrillation. Several pathophysiologic mechanisms (such as structural changes, neurohormonal activation, fibrosis, atherosclerosis, etc.) have been advocated to explain the onset of atrial fibrillation. The presence of atrial fibrillation per se increases the risk of stroke but its coexistence with high blood pressure leads to an abrupt increase of cardiovascular complications. Different risk models are available for the risk stratification and the prevention of thromboembolism in patients with atrial fibrillation. In all of them hypertension is present and is an important risk factor. Antihypertensive treatment may contribute to reduce this risk, and it seems some classes are superior to others in the prevention of new-onset atrial fibrillation and prevention of stroke. Antithrombotic treatment with warfarin is effective in the prevention of thromboembolic events, although quite recently, new classes of anticoagulants that do not require international normalized ratio monitoring have been introduced with promising results.",
keywords = "anticoagulants, antihypertensive treatment, atrial fibrillation, hypertension",
author = "Manolis, {Athanasios J.} and Rosei, {Enrico Agabiti} and Antonio Coca and Renata Cifkova and Erdine, {Serap E.} and Sverre Kjeldsen and Lip, {Gregory Y H} and Krzysztof Narkiewicz and Gianfranco Parati and Josep Redon and Roland Schmieder and Costas Tsioufis and Giuseppe Mancia",
year = "2012",
month = "2",
doi = "10.1097/HJH.0b013e32834f03bf",
language = "English",
volume = "30",
pages = "239--252",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Hypertension and atrial fibrillation

T2 - Diagnostic approach, prevention and treatment. Position paper of the Working Group 'Hypertension Arrhythmias and Thrombosis' of the European Society of Hypertension

AU - Manolis, Athanasios J.

AU - Rosei, Enrico Agabiti

AU - Coca, Antonio

AU - Cifkova, Renata

AU - Erdine, Serap E.

AU - Kjeldsen, Sverre

AU - Lip, Gregory Y H

AU - Narkiewicz, Krzysztof

AU - Parati, Gianfranco

AU - Redon, Josep

AU - Schmieder, Roland

AU - Tsioufis, Costas

AU - Mancia, Giuseppe

PY - 2012/2

Y1 - 2012/2

N2 - Hypertension is the most common cardiovascular disorder and atrial fibrillation is the most common clinically significant arrhythmia. Both these conditions frequently coexist and their prevalence increases rapidly with aging. There are different risk factors and clinical conditions predisposing to the development of atrial fibrillation, but due its high prevalence, hypertension is still the main risk factor for the development of atrial fibrillation. Several pathophysiologic mechanisms (such as structural changes, neurohormonal activation, fibrosis, atherosclerosis, etc.) have been advocated to explain the onset of atrial fibrillation. The presence of atrial fibrillation per se increases the risk of stroke but its coexistence with high blood pressure leads to an abrupt increase of cardiovascular complications. Different risk models are available for the risk stratification and the prevention of thromboembolism in patients with atrial fibrillation. In all of them hypertension is present and is an important risk factor. Antihypertensive treatment may contribute to reduce this risk, and it seems some classes are superior to others in the prevention of new-onset atrial fibrillation and prevention of stroke. Antithrombotic treatment with warfarin is effective in the prevention of thromboembolic events, although quite recently, new classes of anticoagulants that do not require international normalized ratio monitoring have been introduced with promising results.

AB - Hypertension is the most common cardiovascular disorder and atrial fibrillation is the most common clinically significant arrhythmia. Both these conditions frequently coexist and their prevalence increases rapidly with aging. There are different risk factors and clinical conditions predisposing to the development of atrial fibrillation, but due its high prevalence, hypertension is still the main risk factor for the development of atrial fibrillation. Several pathophysiologic mechanisms (such as structural changes, neurohormonal activation, fibrosis, atherosclerosis, etc.) have been advocated to explain the onset of atrial fibrillation. The presence of atrial fibrillation per se increases the risk of stroke but its coexistence with high blood pressure leads to an abrupt increase of cardiovascular complications. Different risk models are available for the risk stratification and the prevention of thromboembolism in patients with atrial fibrillation. In all of them hypertension is present and is an important risk factor. Antihypertensive treatment may contribute to reduce this risk, and it seems some classes are superior to others in the prevention of new-onset atrial fibrillation and prevention of stroke. Antithrombotic treatment with warfarin is effective in the prevention of thromboembolic events, although quite recently, new classes of anticoagulants that do not require international normalized ratio monitoring have been introduced with promising results.

KW - anticoagulants

KW - antihypertensive treatment

KW - atrial fibrillation

KW - hypertension

UR - http://www.scopus.com/inward/record.url?scp=84855852531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855852531&partnerID=8YFLogxK

U2 - 10.1097/HJH.0b013e32834f03bf

DO - 10.1097/HJH.0b013e32834f03bf

M3 - Article

VL - 30

SP - 239

EP - 252

JO - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

IS - 2

ER -